IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v539y2016i7629d10.1038_nature20554.html
   My bibliography  Save this article

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

Author

Listed:
  • Olivier De Henau

    (Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory)

  • Matthew Rausch

    (Infinity Pharmaceuticals, Inc.)

  • David Winkler

    (Infinity Pharmaceuticals, Inc.)

  • Luis Felipe Campesato

    (Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory)

  • Cailian Liu

    (Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory)

  • Daniel Hirschhorn Cymerman

    (Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory)

  • Sadna Budhu

    (Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory)

  • Arnab Ghosh

    (Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory)

  • Melissa Pink

    (Infinity Pharmaceuticals, Inc.)

  • Jeremy Tchaicha

    (Infinity Pharmaceuticals, Inc.)

  • Mark Douglas

    (Infinity Pharmaceuticals, Inc.)

  • Thomas Tibbitts

    (Infinity Pharmaceuticals, Inc.)

  • Sujata Sharma

    (Infinity Pharmaceuticals, Inc.)

  • Jennifer Proctor

    (Infinity Pharmaceuticals, Inc.)

  • Nicole Kosmider

    (Infinity Pharmaceuticals, Inc.)

  • Kerry White

    (Infinity Pharmaceuticals, Inc.)

  • Howard Stern

    (Infinity Pharmaceuticals, Inc.)

  • John Soglia

    (Infinity Pharmaceuticals, Inc.)

  • Julian Adams

    (Infinity Pharmaceuticals, Inc.)

  • Vito J. Palombella

    (Infinity Pharmaceuticals, Inc.)

  • Karen McGovern

    (Infinity Pharmaceuticals, Inc.)

  • Jeffery L. Kutok

    (Infinity Pharmaceuticals, Inc.)

  • Jedd D. Wolchok

    (Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory
    Weill Cornell Medical and Graduate Schools)

  • Taha Merghoub

    (Memorial Sloan Kettering Cancer Center, Parker Institute for Cancer Immunotherapy and Swim Across America/Ludwig Collaborative Laboratory)

Abstract

Targeting tumour-infiltrating suppressive myeloid cells with a selective PI3Kγ inhibitor overcomes resistance to checkpoint blockade therapy in various mouse myeloid-rich tumour models.

Suggested Citation

  • Olivier De Henau & Matthew Rausch & David Winkler & Luis Felipe Campesato & Cailian Liu & Daniel Hirschhorn Cymerman & Sadna Budhu & Arnab Ghosh & Melissa Pink & Jeremy Tchaicha & Mark Douglas & Thoma, 2016. "Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells," Nature, Nature, vol. 539(7629), pages 443-447, November.
    • Handle: RePEc:nat:nature:v:539:y:2016:i:7629:d:10.1038_nature20554
    DOI: 10.1038/nature20554
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature20554
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature20554?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Yonghyun Lee & Jongyoon Shinn & Cheng Xu & Hannah E. Dobson & Nouri Neamati & James J. Moon, 2023. "Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    2. Mingming Zhao & Xiaohui Cheng & Pingwen Shao & Yao Dong & Yongjie Wu & Lin Xiao & Zhiying Cui & Xuedi Sun & Chuancheng Gao & Jiangning Chen & Zhen Huang & Junfeng Zhang, 2024. "Bacterial protoplast-derived nanovesicles carrying CRISPR-Cas9 tools re-educate tumor-associated macrophages for enhanced cancer immunotherapy," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    3. Fengqiao Li & Xue-Qing Zhang & William Ho & Maoping Tang & Zhongyu Li & Lei Bu & Xiaoyang Xu, 2023. "mRNA lipid nanoparticle-mediated pyroptosis sensitizes immunologically cold tumors to checkpoint immunotherapy," Nature Communications, Nature, vol. 14(1), pages 1-16, December.
    4. Charlotte R. Bell & Victoria S. Pelly & Agrin Moeini & Shih-Chieh Chiang & Eimear Flanagan & Christian P. Bromley & Christopher Clark & Charles H. Earnshaw & Maria A. Koufaki & Eduardo Bonavita & Sant, 2022. "Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    5. Xin Guan & Liping Sun & Yuting Shen & Fengshan Jin & Xiaowan Bo & Chunyan Zhu & Xiaoxia Han & Xiaolong Li & Yu Chen & Huixiong Xu & Wenwen Yue, 2022. "Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis," Nature Communications, Nature, vol. 13(1), pages 1-17, December.
    6. Lei Zhang & Li Jiang & Liang Yu & Qin Li & Xiangjun Tian & Jingquan He & Ling Zeng & Yuqin Yang & Chaoran Wang & Yuhan Wei & Xiaoyue Jiang & Jing Li & Xiaolu Ge & Qisheng Gu & Jikun Li & Di Wu & Antho, 2022. "Inhibition of UBA6 by inosine augments tumour immunogenicity and responses," Nature Communications, Nature, vol. 13(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:539:y:2016:i:7629:d:10.1038_nature20554. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.